320 related articles for article (PubMed ID: 20698202)
1. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Qun W; Tao Y
Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
[TBL] [Abstract][Full Text] [Related]
2. [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
Tanida T; Tanemura M; Kobayashi S; Wada H; Marubashi S; Eguchi H; Takeda Y; Umeshita H; Mori M; Doki Y; Nagano H
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2729-31. PubMed ID: 21224694
[TBL] [Abstract][Full Text] [Related]
3. [A case of intrahepatic cholangiocarcinoma successfully treated by hepatic arterial infusion chemotherapy].
Kudoh K; Doi K; Ohchi T; Ogata K; Matsuo A; Ohtao R; Sugimura H; Muranaka T
Gan To Kagaku Ryoho; 2007 Nov; 34(12):1993-5. PubMed ID: 18219876
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma.
Shitara K; Ikami I; Munakata M; Muto O; Sakata Y
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):241-6. PubMed ID: 18222071
[TBL] [Abstract][Full Text] [Related]
5. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
LaRocca RV; Hicks MD; Mull L; Foreman B
J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
[TBL] [Abstract][Full Text] [Related]
6. [A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU].
Hasuike Y; Motoori M; Hattori T; Fujita J; Mishima H; Sawamura T; Nishishou I; Kikkawa N; Sai H; Hosoki T; Mitomo M
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1909-12. PubMed ID: 10560423
[TBL] [Abstract][Full Text] [Related]
7. [A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
Nakano H; Sasaki Y; Imaoka S; Furukawa H; Ishikawa O; Kabuto T; Kameyama M; Hiratsuka M; Ohigashi H; Nakamori S; Yasuda T; Iwanaga T
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1603-6. PubMed ID: 8854817
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery.
Todoroki T
Hepatogastroenterology; 2000; 47(33):644-9. PubMed ID: 10919004
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin (FAP)--two cases report].
Wada H; Nagano H; Dono K; Kondo M; Yamamoto T; Ota H; Nakamura M; Yoshioka S; Damdinsuren B; Yubo Y; Marubashi S; Miyamoto A; Umeshita K; Nakamori S; Sakon M; Monden M
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1711-3. PubMed ID: 15553691
[TBL] [Abstract][Full Text] [Related]
10. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2007 May; 73(9):1308-17. PubMed ID: 17266941
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
Ibrahim N; Yu Y; Walsh WR; Yang JL
Oncol Rep; 2012 May; 27(5):1303-11. PubMed ID: 22323095
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis.
Hanazaki K; Kajikawa S; Shimozawa N; Shimada K; Hiraguri M; Koide N; Adachi W; Amano J
Hepatogastroenterology; 2002; 49(44):311-6. PubMed ID: 11995440
[TBL] [Abstract][Full Text] [Related]
15. [Resection of cholangiolocellular carcinoma successfully responding to neoadjuvant hepatic arterial infusion chemotherapy - report of a case].
Nakayama Y; Nakamura N; Ito T; Matsubayashi J; Yogo A; Kitou Y; Hanamoto K; Ura K; Taira K; Oe H; Yoshikawa A; Mitsuyoshi A; Ishigami S; Shirase T; Doi R
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1155-7. PubMed ID: 22790060
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
Heravi M; Tomic N; Liang L; Devic S; Holmes J; Deblois F; Radzioch D; Muanza T
Anticancer Drugs; 2012 Jun; 23(5):525-33. PubMed ID: 22357220
[TBL] [Abstract][Full Text] [Related]
17. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
18. [A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy].
Hayashi N; Hasuike Y; Fukuchi N; Kida H; Tujie M; Yoshida T; Ebisui C; Sakita I; Koshino T; Izumiyama K; Koro T; Fujimoto T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1852-4. PubMed ID: 16315961
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
20. Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Poggi G; Montagna B; Melchiorre F; Quaretti P; Delmonte A; Riccardi A; Tagliaferri B; Sottotetti F; Di Cesare P; Stella MG; Villani L; Zorzetto M; Greco G; Cornalba G; Bernardo G
Anticancer Res; 2011 Nov; 31(11):3927-33. PubMed ID: 22110221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
